stockrowZymeworks Inc.
ZYME Healthcare Biotechnology
Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024.
- Revenue
- −90.6%
- EPS
- −2,166.7%
- Free cash flow
- −385.5%
Quarter to June 2026, against a year earlier
Follow ZYME
Alert me
Zymeworks Inc. (ZYME) Gross margin
Zymeworks Inc.'s gross margin over the twelve months to 30 June 2026 was −246.7%, down 217.4 percentage points from fiscal 2025 (−29.3%). Over the past ten years it has ranged from −648.7% (fiscal 2021) to 49.4% (fiscal 2022); the current reading is higher than 73% of that period. That is below the Biotechnology industry median of 65.2% and below the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | −29.3% | 47.14 |
| FY2024 | −76.4% | 12.51 |
| FY2023 | −88.9% | (138.37) |
| FY2022 | 49.4% | 698.13 |
| FY2021 | −648.7% | (309.17) |
| FY2020 | −339.5% | (47.23) |
| FY2019 | −292.3% | (284.93) |
| FY2018 | −7.37% | (26.71) |
| FY2017 | 19.3% | 253.76 |
| FY2016 | −234.4% | (79.20) |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Jun 2026 | −497.7% | 833.23 |
| Mar 2026 | −1,330.9% | (188.99) |
| Dec 2025 | −1,142.0% | (1,113.11) |
| Sep 2025 | −28.8% | (58.14) |
| 38 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| IMNM Immunome, Inc. compare | 100.0% |
| SEPN Septerna, Inc. compare | 100.0% |
| AUPH Aurinia Pharmaceuticals Inc compare | 90.6% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 89.8% |
| VCEL Vericel Corporation compare | 74.5% |
| VERA Vera Therapeutics, Inc. compare | 0.00% |
| BHVN Biohaven Ltd. compare | 0.00% |
| ZYME Zymeworks Inc. | −246.7% |
| COAG Hemab Therapeutics Holdings, Inc. compare | — |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on ZYME
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement